Publications en collaboration avec des chercheurs de Hospital Universitario Central de Asturias (2)

2021

  1. SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation

    Journal for ImmunoTherapy of Cancer, Vol. 9, Núm. 3

2019

  1. YES1 drives lung cancer growth and progression and predicts sensitivity to dasatinib

    American Journal of Respiratory and Critical Care Medicine, Vol. 200, Núm. 7, pp. 888-899